Today, the world has a total population of 6.7 billion people of which nearly 60% are located in Asia. With Asia being one of the fastest growing regions in the world, its clinical trial environment has advanced substantially as governments continue to leverage their healthcare environments. By 2011, 37% of the total clinical trials worldwide will likely shift to Asia. The significant market potential is only one of the many attractions that captivate the interests of biopharmaceutical and medical device industries worldwide to the region.
Click Image to Enlarge
Asian countries such as Japan, South Korea and Taiwan continue to attempt to leverage the living and healthcare standards through reforms and foreign-assisted projects, parallel efforts in refining their regulations on drug and medical development, making Asia a competitive landscape to conduct clinical trials.
PAREXEL’s strong presence and expertise in the region can assist you in developing your full phase clinical trials and penetrate into new markets. By involving Asia as part of your global and regional clinical trials strategies, you could gain access to the following benefits:
